Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
strange way of being a shareholder!
Thank you
you made me laugh!
with all the time and energy you put into it...
LOL
Thank you
I imagine you well convinced while you say it!
tight black latex dress… whip in hand!
The premises are good based on the comment of Ricardo Estape!
They will arrive soon!
In the meantime, you can pour out doubts
luckily he didn't go on!
the market told him no!
bringing on the market a machine that had aspects to improve did not find funds!
SPORT was an advance but the surgeons weren't enthusiastic about it!
SPORT forced TMDI not to look on the market to find funds!
there was someone who played short
ah how much money they made!
Perhaps it is ISRG that pays the strategy ... according to them!
But now TMDI has something that surgeons like ... it has something that MDT also likes ...
ooOOoo
I take a handful these days!
McNally has always worked with the gun pointed!
For me he is OK!
I think what happened last Thanksgiving Day is significant!
Let's hope Big Jim shows up!
come on, come to dad
what's it like to know that it only falls on short sales?
the market is full of decoy!
Vicarious is aiming to make a 510(k) submission in 2023 and grow sales to $1 billion by 2027 but will face strong competition from medtech giants such as Intuitive Surgical, Johnson & Johnson and Medtronic.
The approach is interesting!
They understood everything!
Others have thrown away bilion of $ because they have the wrong approach!
LOL
Do you pump when you open short positions?
who is the major shareholder of tmdi?
here really no one can know how it will go!
Will IDE be a success?
I think the games will be clear after IDE and meanwhile there are those who speculate knowing that the road is still uphill!
TMDI needs marketing and sales help!
Even the stones know it!
But the game here could change your life!
so I play!
Buhahahahhahahahah
For what?
I have 28.000 at 2,02 now
I wait you
I sold over 3,10 but i wanna rebuy
The question is: why is anyone willing to pay these subjects to constantly write badly?
I can't believe there are losers behind them, just to take revenge!
All this prompts me to add!
Target another 10,000 by the end of October!
"A ui ue, luck comes to me! Ui ue ua, luck comes here to us"
HOLD
MC 61,3
$78.5M cash on hand
$34.25M Outstanding Debts
$125M Current Fleet Valuation
Total Asset Valuation = $203.5M
$203.5M (Assets) - $34.5M (Debt) = $169.5M
I've been waiting for 2.5 for 3/4 months!
I have a few and would like to get many at the recommended price from the shorts!
HOLD
MC 64,6
$78.5M cash on hand
$34.25M Outstanding Debts
$125M Current Fleet Valuation
Total Asset Valuation = $203.5M
$203.5M (Assets) - $34.5M (Debt) = $169.5M
there is an analysis...
TP $6
but they missed 35%...
assuming the analysis is reliable (but it is not)
4 days for PAC data on COVID,
honestly I don't expect anything!
Of course if these data justify a phase III it becomes interesting but a bit like for aGVHD... everything is fine!
The brick is like the pussy!
Pulls more of a pussy hair than a cart of oxen! (or... A pussy hair pulls much more than a cart of oxen! or A hair of pussy pulls a lot more than a cart of oxen!... I don't know which is the best form)
If the brick goes well, the economy is really expanding!
TMDI has never been in a better position!
The price is ridiculous!
I wouldn't even sell it for $5
OTB
Globus Maritime Limited (the “Company” or "Globus") (NASDAQ: GLBS), a dry bulk shipping company, announced today that it will release financial results for the quarter and six-month period ended June 30, 2021, after the market closes in New York on Monday, September 27, 2021.
almost almost a bit more
Net revenues was RMB2,232.3 million, a 35.3% year-over-year increase.
Net revenues of online K-12 courses increased 51.0% year-over-year to RMB2,091.4 million.
Gross billings[2] was RMB2,694.7 million, a 12.2% year-over-year increase.
Gross billings of online K-12 courses increased 17.2% year-over-year to RMB2,574.5 million.
Paid course enrollments[3] increased 4.1% year-over-year to 1,631 thousand.
Paid course enrollments of online K-12 increased 4.5% year-over-year to 1,563 thousand.
Net loss was RMB918.8 million, compared with net income of RMB18.6 million in the same period of 2020.
Non-GAAP net loss was RMB763.9 million, compared with non-GAAP net income of RMB72.7 million in the same period of 2020.
Deferred revenue was RMB1,976.4 million, compared with RMB2,733.7 million as of December 31, 2020.
Second Quarter 2021 Key Financial and Operating Data
(In thousands of RMB, except for paid course enrollments and percentages)
Three Months Ended June 30,
2020 2021
Pct. Change Net revenues
1,650,314 2,232,254
35.3%
K-12 courses
1,384,968 2,091,355
51.0%
Foreign language, professional, admission and
other services
265,346 140,899
(46.9%)
Gross billings
2,400,996 2,694,732
12.2%
K-12 courses
2,196,077 2,574,536
17.2%
Foreign language, professional, admission and
other services
204,919 120,196
(41.3%)
Paid course enrollments (In thousands)
1,567 1,631
4.1%
K-12 courses
1,496 1,563
4.5%
Foreign language, professional, admission and
other services
71 68
(4.2)%
Net income (loss)
18,627 (918,791)
NM
Non-GAAP net income (loss)
72,712 (763,890)
In the second quarter of 2021, our revenue has reached a record high of RMB 2.232 billion.
Selling expenses margin in the quarter has also substantially dropped and has reverted to a similar low level that we recorded a year ago, and we have entirely stopped new fee advertising spending since mid-May this year. As you all know, the education industry has experienced some changes over the past few months. However, as the saying goes, we will begin with the end in mind when setting our strategy. We will always remain committed to our original aspiration of quality education, and we will seek to provide authentic educational services.
In the meantime, we have actively shouldered our social responsibility at our education company. Ever since May, we have successfully collaborated with multiple nonprofit organization, including the China Charity's Aid Foundation for Children, the China Youth Development Foundation and the China Next Generation Education Foundation, and the Henan Normal University by donating cash or free courses to aid the revitalization of rural area education and supporting the goal of providing equal access to education for all. To actively respond to the nation's call, we had recently and rapidly adopted the organizational structure of our company to focus on professional education and STEAM education. And we are further exploring opportunities related to digital products and vocational education.
First, we will continue to expand our investments in our existing professional education segments, such as financial certificate and the public office exam preparation, while constantly exploring more professional education portfolio opportunities, such as post-graduate exam preparation and overseas studies preparation, among which some have already achieved a better-than-industry average online. We aim to establish a diversified professional education portfolio with multiple segments. Secondly, we have also increased our investments in our STEAM education segment, which is developing rapidly. Take programming as an example.
Just in July 2021, the conversion rate from trial classes to regular price for courses exceeded 30%. Thirdly, we are simultaneously exploring new opportunities in various products and vocational education, continuing to reinforce the positive effect, technology and education content, and education tools and expanding our footprint across the education sector. We firmly believe that the education market in China will continue to grow steadily. We also firmly believe that the current education firm will play a very important role in the education.
We are confident that our company will live up to our responsibilities and mission. Since spring, we have made numerous breakthroughs in the K-12 area, including streamlining higher industry supply chain, refining the standard procedures, training experts, teachers at scale, constructing effective services, and improving operational efficiencies, all of which helped us accumulate a great deal of insight and expertise. We now plan to replicate this insight and expertise to STEAM education, professional education, and vocational education. And we sincerely hope that we can soon return to the profitable growth trajectory that we saw back in 2019.
As many of you know, our company experienced a severe cash shortage in 2016 and 2017 and almost went bankrupt. We call it the darkest moment internally. But it was exactly and that pressure that we came together as a united and effective team with tremendous, coherent and the best execution to build a miraculous business that generated rapid revenue growth and growing profitability over seven consecutive quarters. If 2014 was our first time as a start-up and 2015 was our second start, then we can say that 2021 is our third start.
As someone who has worked in the education industry for 33 years, I believe we should always have love for our family and our country, always keep the end goal of education in mind, always firmly believe that education is a noble profession and always have faith that the future ahead is bright, both for our industry and our society. Now I will pass the call over to our CFO, Shannon, to walk you through our financial and operational details.
you know how many are trying, how much they have all spent and where they are!
you know what it means to create a product that can work in the surgical field!
who is ahead of all on SP?
who has the least cumbersome and economical solution?
who is the most underestimated?
TMDI have to overcome several challenges as an IDE, but do you want to put where I prefer to be?
precisely because they can no longer be wrong!
I love what they are doing and how they are doing it ... timely manner ... like never before
I'm not impressed with Vicarious as an investment, right now, and I wish you that I never will
Why do you wait until they have no more restrictions?
It might be too late!
maybe in about ten years, after the huge wall of development for commercialization has been overcome ... I'll give it a thought!
Thanks it's always important to know what others are doing!
Curious that they are developing the road opened by TMDI...
I read from Mc's face that Milestone 4 is archived! He wanted to say it but couldn't for obvious reasons!
For me, body language matters more than words!
tic toc tic toc tic toc!
that 20% will make the difference ...
Pareto teaches!
Mc knows that there is someone on the market who will win anyway! If it goes wrong he will sink the boat but if he goes well he will win anyway!
Nothing is decided and everything is possible!
When the product is marketable, in my opinion, MDT will take the opportunity!
If I were MDT, I might have a great interest in keeping the stock of TMDI down! But that's not their style!
MDT is number 1!
the shorts pump when they are opening the short position ... the more they take at high prices the more they will earn when they start complaining! the cat and the fox are crafty but too stingy!
the construction of the ENOS prototype for IDE is near ... it will be exciting
The NDA submission is a major milestone in making linzagolix available in the U.S., and an important step toward addressing the diverse medical needs that exist for women with uterine fibroids,” said Brian O’Callaghan, CEO of ObsEva. “Our positive Phase 3 PRIMROSE results underscore linzagolix’s clinical utility and well-known differentiated profile. If approved, linzagolix will be the first oral GnRH antagonist to offer treatment options for women who cannot or do not want to take hormones, as well as for women who are able to take additional hormone therapy. We look forward to overcoming existing challenges in the treatment of uterine fibroids -- with linzagolix’s unique low-dose option (100 mg without ABT) and high dose option (200 mg with ABT) -- and will work with the FDA through the regulatory process as we prepare for commercialization.”
Concurrently, ObsEva is also working closely with the European Medicine Agency’s (EMA) to achieve marketing approval. Linzagolix previously received validation of the marketing authorization application (MAA) with an approval recommendation from the Committee for Medicinal Products for Human Use (CHMP) expected in Q4 2021.
powerful these 30 shares
LOL
the supercazzola spare it to us!
If there are some proud shorts that push and sell!
The market is not helping them!
Inflation does not gallop!
Patents arrive as if it were raining!
The shareholders may be small but they hold!
Their only hope is Aspire... But not for now! Ouch them!
So why did they ask for people involved in mergers to be included in the BOD?
And in MDT
https://www.linkedin.com/posts/activity-6813147880220585984-qpWi
https://journey.ct.events/view/6ab223b3-2e1c-490c-a51f-44f7b036ffab
It works
just enter the e-mail address and the registration starts ... any email
In the era of immediate news, does it make sense to do these presentations?
McNally inherited a hot potato... he got burned but learned to handle it!
The potato still burns.
I trust more and more!
they do whatever they have to do... I think it will go up soon